About: http://webisa.webdatacommons.org/391009385

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	He said this is a rare event, and that in the IRIS, DASISION, and ENESTnd trials the risk of progression for imatinib in the control arm in the first two to three years was a consistent five to six percent.
http://www.w3.org/ns/prov#wasQuotedFrom	lww.com